News Article | May 11, 2017
"Employees who are satisfied in their work are the bedrock of our company's triple bottom line commitment to people, planet and profits," said Patti Poppe, Consumers Energy's president and chief executive officer. "We are gratified that our own employees recommend Consumers Energy as a place that's great to work, and are proud to have a workplace culture that supports rewarding careers and world-class service to our customers." Consumers Energy has undertaken various efforts to create a strong, vibrant workplace. The company supports resource groups for employees of different backgrounds and last year was recognized as a silver level Veteran-Friendly Employer by the Michigan Veterans Affairs Agency. "We have worked hard in recent years to listen to our employees and use their ideas to make our company stronger," said Cathy Hendrian, Consumers Energy's senior vice president of human resources. "We measure our performance in terms of employees' benefits, productivity and morale against our peers and against employers outside our industry to make sure we're attracting and retaining the best and brightest people to serve our state." In addition, Consumers Energy and employees supported a successful effort in the company's hometown of Jackson to develop a citywide non-discrimination ordinance. The Jackson City Council approved the legislation in February. Consumers Energy, Michigan's largest utility, is the principal subsidiary of CMS Energy (NYSE: CMS), providing natural gas and electricity to 6.7 million of the state's 10 million residents in all 68 Lower Peninsula counties. For more information about Consumers Energy, go to www.ConsumersEnergy.com. READ THE STORY: Read Forbes magazine's story about America's best employers and see its complete rankings: www.forbes.com/sites/jeffkauflin/2017/05/09/americas-best-employers-2017 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/consumers-energy-recognized-by-forbes-magazine-as-michigans-best-employer-in-national-survey-300455824.html
News Article | May 9, 2017
"Over the past month, Wounded Warrior Project has engaged in productive dialogue with VA, lawmakers on Capitol Hill, and fellow veterans service organizations to discuss the issues with the caregiver program and to propose solutions," said WWP CEO Lt. Gen. (Ret.) Mike Linnington. "I applaud VA for taking a look into the program, and I strongly urge VA to consider these recommendations to improve consistency, fairness, and transparency, and to provide support for those transitioning out of the program." WWP championed legislation in 2010 to create the caregiver program. While it provides crucial support to numerous families, WWP continues to hear concerns from caregivers and veterans. WWP shared these concerns with VA. Additionally, WWP participated in meetings with White House officials and VA leadership; met with the House Veterans Affairs Committee Subcommittee on Health; delivered a letter to VA Secretary Shulkin offering to host a discussion with caregivers; and has met multiple times with fellow veterans service organizations to propose solutions for the program. Caregivers provide a vital service, often giving up careers and opportunities in order to care for our nation's heroes. We owe it to them to provide the support they need. WWP is dedicated to continuing this collaborative work with VA, Congress, the administration, and partner veterans service organizations to ensure the caregiver program provides support to those who care for the most seriously injured. About Wounded Warrior Project Wounded Warrior Project® (WWP) connects, serves, and empowers wounded warriors. Read more at http://newsroom.woundedwarriorproject.org/about-us. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wounded-warrior-project-recommends-improvements-to-vas-caregiver-program-300454608.html
News Article | May 12, 2017
MOUNTAIN HOME, TN--(Marketwired - May 12, 2017) - The U.S. Department of Veterans Affairs on May 12 released a solicitation in which it outlined plans to acquire non-emergent wheelchair transportation services in Mountain Home, Tennessee. The contractor who receives this contract must be a certified service-disabled veteran-owned small business (SDVOSB) and provide 24-hour, seven day per week non-emergent wheelchair transportation services for beneficiaries of the James H. Quillen Mountain Home VA Medical Center. The performance period shall be from the date of award through September 30, 2017, with the VA retaining the right to award four optional renewal periods of one year each. The NAICS Code is 485991, and the Size Standard is $7 million. Responses are due by no later than May 16, 2017 and can be emailed to Stacey McClendon at Stacey.Mcclendon4@va.gov. The contractor who receives this contract must be registered with the System for Award Management (SAM) database and have as part of the Registration all current Representations and Certifications. US Federal Contractor Registration, the world's largest third-party government registration firm, completes the required Registrations on behalf of its clients. It also makes available information about opportunities like this, as well as training on how to locate, research, and respond to opportunities. We also make available for our clients and for contracting officers our proprietary Advanced Federal Procurement Data Search (AFPDS). Our Advanced Federal Procurement Data Search (AFPDS) gives you in one place instant bid notifications, bid proposal prospecting, and information about government procurement officers. We make this search tool available to clients, as part of our commitment to helping each and every USFCR client succeed and thrive as a government contractor. For contracting officers, the AFPDS gives them in one place access to a database of available contractors and also a place to post information about opportunities. Contracting officers get free access to AFPDS. We also provide interested contracting officers a list of contractors who may be able to provide a service and/or product that they need. For more information, to get started with a SAM registration or to learn more about how US Federal Contractor Registration can help your business succeed, call 877-252-2700, ext. 1.
News Article | May 10, 2017
WASHINGTON--(BUSINESS WIRE)--The U.S. Department of Veterans Affairs (VA), the Veterans of Foreign Wars of the U.S. (VFW) and drugstore chain Walgreens announced a collaborative agreement May 6, which will help improve mental health care for Veterans through enhanced education, access to resources and outreach. VA, VFW and Walgreens will work together to reach Veterans in communities across the country with targeted initiatives to address mental health awareness and treatment, Veteran suicide prevention and opioid overdose education. “Our work is driven by our commitment to encourage Veterans to get the care and services they need and integrate mental health care as part of their overall wellness and healthy lifestyle,” said VA Secretary Dr. David J. Shulkin. “Joining forces with VFW and Walgreens provides VA an opportunity to further expand our reach and connect with Veterans, their families and the community to raise mental health awareness.” As part of the collaboration, VA, VFW and Walgreens will: “We know that the rate of suicide is increasing for all Americans, but the rate of increase is much slower for Veterans who receive VA care,” said Dr. Poonam Alaigh, Acting VA Under Secretary for Health. “With this in mind, we need to cast a wider net and meet Veterans where they live to better engage them in care.” “The mental well-being of America’s Veterans is of the utmost importance to the VFW,” said VFW National Commander Brian Duffy. “By working with several organizations including Walgreens and VA, we’re able to positively impact a great number of Veterans, and help to change the narrative associated with mental wellness.” “We’re proud of the collaborations we’ve developed to provide greater access to pharmacy and health-care services for current and former members of the armed services, including retirees and their families,” said Brad Fluegel, Walgreens Chief Healthcare Commercial Market Development Officer. “We look forward to working closely with VA and VFW to help heighten mental-health awareness and hope to improve the health and well-being of more Veterans by connecting them with VA, VFW and other resources that can help.” VA is a leader in educating patients about the risks of opioids, including opioid medications and dispensing naloxone to interested patients. To date, VA has issued naloxone to more than 60,000 Veterans to prevent overdose. Separately, other pharmacies, including Walgreens, have installed safe, medication-disposal kiosks and made naloxone available without requiring a prescription. For more information about VA mental health services, visit http://www.mentalhealth.va.gov. Information about VFW may be found at www.vfw.org. More information about Walgreens may be found at www.walgreens.com.
News Article | May 9, 2017
Wichita, KS, May 09, 2017 (GLOBE NEWSWIRE) -- WICHITA, Kan. – The U.S. Department of Veterans Affairs (VA), Center for Verification and Evaluation (CVE), has notified Solid Design Solutions that it has been verified as a Service-Disabled Veteran-Owned Small Business (SDVOSB) and added to the Vendor Information Pages (VIP). This makes the company eligible to participate in the VA’s Veterans First Contracting Program. Solid Design Solutions designs and manufactures machines for the medical, agricultural, industrial and aerospace industries. “This designation means a great deal to our team,” says Pete Gustaf, Solid Design Solutions president and CEO. “As a small business, SDVOSB provides greater opportunities for us to more fully leverage our far-reaching, change-agent products and engineering expertise.” Solid Design Solutions was founded near Minneapolis in 1997. In January 2017, it opened an office in Wichita as a way to capitalize on the community’s Air Capital heritage and reputation for building world-class products. It specializes as an end-to-end, product and specialty machine design firm that helps bring products to market by harnessing clients’ technology, software and models in order to convert them into products that can be produced reliably and consistently. Solid Design Solutions provides industrial design, mechanical, electrical, and software engineering services and develops concepts for assembly, testing and manufacturing procedures. “Having this certification enhances our ability to pursue opportunities,” says Gustaf, “whether winning a project as the prime contractor or partnering with a large prime contractor as subcontractor.” Solid Design Solutions serves clients from entrepreneurial startups to such established, industry titans as 3M, Bose, Boston Scientific, Honeywell, Medtronic and Fastenal. Expertise coupled with state-of-the-art tools allow Solid Design Solutions to deliver value throughout the specialty-machine development process. Its range of medical projects spans from sophisticated assembly systems to complex clean-room process, test and measurement systems. This SDVOSB verification is valid for three years. The Congressional act that established SDVOSB in 1999 sets an annual government-wide goal of not less than 3 percent of the total value of all prime contract and subcontract awards for small businesses owned by service-disabled veterans. “Watch for even more good things to happen at Solid Design Solutions as a result of this designation,” says Gustaf. Since its founding in 1997, Solid Design Solutions has developed a reputation for transforming ideas into market-ready products and highly accurate machine systems. It does so efficiently, cost-effectively and rapidly. Core competencies include industrial design, mechanical and electrical engineering, software/firmware engineering, IoT device development, project management, and global sourcing coordination through new product introduction. The company is based in Mounds View, Minn., and in early 2017 opened an office in Wichita, Kan.
News Article | May 11, 2017
NEW YORK, May 11, 2017 /PRNewswire/ -- This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine (global & USA) market is presented as follows: Read the full report: http://www.reportlinker.com/p03118741/Personalized-Medicine-Targeted-Therapeutics-and-Companion-Diagnostic-Market-to-Strategic-Analysis-of-Industry-Trends-Technologies-Participants-and-Environment.html • By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) • By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) • By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) • By Therapy (Cancer, Cardiovascular, Infectious Disease) Key Opinion Leaders that contributed to interview questions within the report include: • Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group • Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland • Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC • Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland • Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine • Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine • David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine • Deborah Phippard, PhD, Vice President, Research, Precision for Medicine • Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine A wealth of financial data & business strategy information is provided including: • Company financials, sales & revenue figures • Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies • Business Model Strategies for Providers. Provider Systems and Academic Medical Centres • Business Model Strategies for Payers & Governments • Private and Public Funding and Personalized Medicine Reimbursement • Revisions to Current Payment Systems and intellectual property • How to Gain Market Penetration in the EU • Cost-effectiveness and Business Value of Personalized Medicine • Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) • Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: • Key strengths, weaknesses and threats influencing leading player position within the market • Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) • Top fastest growing market segments and emerging opportunities • Top pharmaceutical companies within the IPM by market share and revenue • Comprehensive product portfolios, R&D activity and pipeline therapeutics • M&A activity and future strategies of top personalized medicine pharmacos • Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) • CE-marked Personalized Medicine/Diagnostic Tests • FDA Advances in Personalized Medicine Regulation This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. • 23andMe • Abbott Laboratories • Abbott Molecular Inc. • Admera Health (GENEWIZ) • Affymetrix • Agendia • Alere • Amgen • Astex Pharmaceuticals • AstraZeneca • Atossa Genetics • Becton Dickenson • bioMerieux • BristolMyersSquibb • Cancer Genetics • Celera (Quest Diagnostics) • Celldex Therapeutics • Claritas Genomics • CuraGen • Danaher (Leica Biosystems) • deCode Genetics (Amgen) • Foundation Medicine • EDP Biotech • Eli Lilly • ELDA BioTech • Eisai • Genelex • GlaxoSmithKline • Human Longevity Inc (Cypher Genomics) • HalioDx • Ikonisys • Illumina • InterGenetics • Johnson & Johnson • LabCorp • Life Technologies • Merck • MDxHealth • MolecularMD Corporation • Monogram Biosciences • Myriad • Nodality • Novartis MDx • Orion Genomics • Oxford BioTherapeutics • NanoString Technologies • Pfizer • Qiagen • Roche Molecular Diagnostics • Sanofi • SensiGen • Siemens Healthcare Diagnostics • Takeda • Thermo Fisher Scientific • Transgenomic • Ventana (Roche) • Vermillion (Ciphergen) • Vertex Pharmaceuticals What you will gain: • An in-depth understanding of the global personalized medicine market and it's environment • Current market facts, figures and product lines of key players in the industry • Emerging trends in key markets such as the US, UK, Germany and France • Knowledge of how the personalized medicine market will integrate into the global healthcare market • Technical insights into new generation sequencing technologies and ultra-high throughput sequencing • Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies • FDA approved pharmacogenetic tests and recognized biomarkers • Information on key government and regulatory policies • Strategies on how to adapt and restructure current business models to this industry This report tackles key concerns to the personalized medicine market such as: • Lack of regulatory policy and legislation in the US and Europe • Reimbursement schemes and payers concerns • Transition of investigational diagnostic assays and therapeutics to clinical practice • Direct to consumer (DTC) test kits and implications for the public Who should read this report? • Pharmaceutical, biotechnology and diagnostic companies (CEOs, VPs, Business Development, C-Suite)with an interest in personalized medicine • Industry professionals and business strategists will discover key information to propel their policies • Investors will gain inside information to dominant players in the industry and future forecasts • Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment This report will tell you if the companies mentioned are: • Strong, competitive players • Pooling their resources for specific growth and therapeutic areas • Investing strategically in R&D • Have a history of strategic M&A activity This detailed report is supported with 360 figures and tables over 397 pages and profiles the main pharmacos in personalized medicine. Benefits of Investing in our Cutting-Edge Reports: - Clients receive complementary content* with mid-level and enterprise wide licences - Post-sale complementary consultation with senior expert analyst is included - Use of tables and figures in your own reports and presentations is permitted - Each report provides straight-talking strategic analysis & sector intelligence - All reports are updated each quarter to give you the most up-to-date information Executive Summary Kelly Scientific forecasts that the companion diagnostic and targeted therapeutic submarkets of the personalized medicine industry were worth $113 billion in 2016, and will hit over $162 billion by 2021 with a CAGR of 8.74%. The total personalised therapeutic market, for all indications, will be worth $x billion by 2021, with a CAGR of x%. Currently it is estimated that the companion diagnostic segment is worth $x billion globally, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. This is set to rise vertically over the next five years and by 2021 will be worth over $x billion, with a CAGR of x%. This study details a comprehensive financial and strategic review of key players in the personalized medicine industry. Significant drivers and restraints of this market are revealed and market opportunities and challenges are identified. Disruptive technologies that are propelling the personalized medicine and companion diagnostic market are scrutinized. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analysed. This study reveals market figures of the overall personalized medicine market and also sub-market figures with respect to companion diagnostics, targeted cancer therapeutics, medical technologies, pharmacogenomics, consumer genomics, molecular diagnostics and liquid biopsies. Specific indication markets are also included such as cancer, cardiovascular and infectious disease. The report provides value and growth of the global personal therapeutics market from 2017-2021. Also historic figures back to 2014 are given to illustrate growth. As the personal targeted therapeutics market is part of the overall personalized medicine market, the companion diagnostics market is also included in the report The report goes into detail regarding different indications, mainly oncology drugs as these hold most market share, and also cardiovascular and infectious disease markets. It contains specific data for both the targeted therapeutic and companion diagnostic sections of the personalized medicine market. These sections are then further divided into indications – Oncology, Cardiovascular and Infectious Disease The report also analyses the market with regards to major players such as GSK, Amgen, Sanofi, Novartis, Janssen, BMS, Pfizer, AstraZeneca, Roche. To give an comprehensive view of how the PM market relates to associated markets, a number of these are analysed and forecast to 2021 (medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy). For example, data from the targeted therapeutics section includes the following specifics: • Targeted Therapeutic Sales Revenue, All Indications (by Company, GSK, Amgen, Sanofi, Novartis, Janssen, BMS, Pfizer, AstraZeneca, Roche). • Global Targeted Therapeutic Market, All Indications, Forecast 2014-2021 • Global Oncology Targeted Therapeutics Forecast 2014-2021 • HER-2 Positive Breast Cancer Targeted Therapeutic Market Forecast 2014-2021 • Oncology Targeted Therapeutic Market Forecast By Drug 2014-2021 (Herceptin Erbitux Gilotrif Gleevec Mekinist Tafinlar Zelboraf Tarceva Xalkori Zelboraf Kadcyla Perjeta Adcetris Xeloda Afinitor, Faslodex Iressa, Revlimid Avastin Alimta) • Branded Oncology Therapeutics Market Share 2014-2021 (Herceptin Erbitux Gleevec Tarceva Kadcyla Perjeta Xeloda Afinitor Revlimid Avastin Alimta) • Top Pharma Companies Revenue from Targeted Therapeutics in Oncology (Roche, Novartis, Janssen, BMS, AstraZeneca, Sanofi, GSK, Pfizer, Amgen, Eli Lilly) • Branded Cardiovascular Targeted Therapeutic Total Market 2014-2021 • Branded Cardiovascular Targeted Therapeutics Market Forecast by Drug 2014-2021 (Metoprolol, Bidil, Plavix, Carvedilol) • Infectious Disease Targeted Therapeutics Market to 2014 - 2021 • Branded Infectious Disease Targeted Therapeutics Market by Drug 2014-2021 (Incivek, Pegasys, Selzentry, Ziagen, Sovaldi, Harvoni) Similarly, data for the companion diagnostic section is given. Personalized Medicine Targeted Therapeutics – Oncology In order to get an in depth understanding of the oncology therapeutics section within the personalized medicine market it is important to initially review the global oncology therapeutics market. Oncology continues to be an area of high unmet need and product revenue potential. Oncology is the largest global therapeutic area, with global sales of $x billion in 2016; that is anticipated to reach $x billion by 2021. Increasing cancer prevalence globally is a major driver of the market, and this is further underlined by more sensitive diagnostics and screening methods. The predicted revenue growth in the oncology space is reinforced by increasing cancer prevalence, as well as advances in diagnosis methods and screening programs. The current trend is that patients are advancing to 2nd, 3rd and 4th line therapy regimes, and so this progression further expands the market. A significant driver of revenue growth is the cost of oncology therapeutics and biologics. For example, Yervoy (BMS) annual costs are $x for four doses. Another example is Dendreon's Provenge which has an annual cost of $x for three doses. This significant increase in the price of oncology therapeutics has expanded the market, even though price reductions have been fought for by payers. Targeted Cancer Therapeutics Targeted cancer therapeutic sales have significantly risen in the recent past with a x% increase from 2013 to 2014 alone. The global oncology market is currently booming and one of the main reasons for this increase is the dramatic rise in the number of prescribed targeted therapies. The market is also growing in size as the cost of targeted therapeutics is high. This is due to longer treatment times, increased investment and development costs. Targeted therapeutics also are, by definition, designed to treat smaller cohorts of patients, albeit more effectively. Therefore, pharmaco's need to recoup costs via pricing. Two major targeted therapeutics on the market are Roche's melanoma agent Zelboraf and Pfizer's lung cancer agent Xalkori. Zelboraf (vemurafenib) is a MEK inhibitor indicated for skin cancer and in FY2013 reached $x million. Xalkori (crizotinib) is indicated in patients positive for an ALK mutation and has an annual sale figure of €x million. Top Ten Companies in Oncology Drug Sales Roche Holdings continues to occupy its first position in oncology market. The company's sales performance was driven by HER 2-positive breast cancer therapies. Globally, it is the largest maker of cancer treatments and mainly focuses on biologic drugs. Most of its cancer drugs are developed by California-based Genentech, a pioneer in biologic therapies that Roche acquired in 2009. Worldwide sales of Herceptin, that is about to lose patent protection year, rose 9%. But sales of Perjeta and Kadcyla, two follow-on therapies, increased by triple-digit percentages, drawing attention to the company's success in developing successor products. Roche is pinning its hopes on follow-on products to preserve its place in the market once generic competition, known as biosimilars, begin to appear. These biologic therapies usually have higher margins than conventional drugs and are more difficult to copy. Bristol-Myers Squibb's overall sales rose by about x% only, but its cancer immunotherapy drugs witnessed huge sales gains. Its Yervoy, a skin-cancer immunotherapy, leaped x% to $x million in the fourth quarter, while Opdivo, another skin-cancer drug approved in late December 2014, contributed sales of $x million. The company's sales of leukemia drug Sprycel rose x% to $x million in 2016. Celgene Corporation has reported that its revenue rose in the most recent period, driven by sales growth of its key cancer treatment, particularly in the U.S. The company expects 2015 to be an important year for Revlimid, a blockbuster blood-cancer drug, which will be tested in trials for treatment of a kind of lymphoma. The FDA is expected to decide whether the drug can be used to treat newly diagnosed multiple myeloma. Regulatory bodies in the U.S. and the E.U. are making key decisions on the drug. Revlimid sales increased x% to $x billion in the most recent quarter, as market share expanded along with the duration of therapy. U.S. sales of the drug grew by x% while international sales increased x%. The personalized medicine, targeted therapeutic and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Companies Mentioned • 23andMe • Abbott Laboratories • Abbott Molecular Inc. • Admera Health (GENEWIZ) • Affymetrix • Agendia • Alere • Amgen • Astex Pharmaceuticals • AstraZeneca • Atossa Genetics • Becton Dickenson • bioMerieux • BristolMyersSquibb • Cancer Genetics • Celera (Quest Diagnostics) • Celldex Therapeutics • Claritas Genomics • CuraGen • Danaher (Leica Biosystems) • deCode Genetics (Amgen) • Foundation Medicine • EDP Biotech • Eli Lilly • ELDA BioTech • Eisai • Genelex • GlaxoSmithKline • Human Longevity Inc (Cypher Genomics) • HalioDx • Ikonisys • Illumina • InterGenetics • Johnson & Johnson • LabCorp • Life Technologies • Merck • MDxHealth • MolecularMD Corporation • Monogram Biosciences • Myriad • Nodality • Novartis MDx • Orion Genomics • Oxford BioTherapeutics • NanoString Technologies • Pfizer • Qiagen • Roche Molecular Diagnostics • Sanofi • SensiGen • Siemens Healthcare Diagnostics • Takeda • Thermo Fisher Scientific • Transgenomic • Ventana (Roche) • Vermillion (Ciphergen) • Vertex Pharmaceuticals Read the full report: http://www.reportlinker.com/p03118741/Personalized-Medicine-Targeted-Therapeutics-and-Companion-Diagnostic-Market-to-Strategic-Analysis-of-Industry-Trends-Technologies-Participants-and-Environment.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/personalized-medicine-targeted-therapeutics-and-companion-diagnostic-market-to-2021--strategic-analysis-of-industry-trends-technologies-participants-and-environment-300456319.html
News Article | May 8, 2017
The objectives of the meeting are to identify both the current state of and the greatest opportunities in the three identified aspects of primary palliative nursing. The post meeting objectives are to develop an implementation plan, and to identify strategies to address the greatest opportunities to help nursing transform the care and culture of serious illness. National initiatives over the last few years have helped set the stage for this summit by identifying significant opportunities to enhance care delivery models and systems. Those gathering from the nursing community at the summit will help create a collaborative agenda to focus on how nurses lead and transform care for individuals and their families who are facing serious illness. Attending organizations include the Academy of Medical-Surgical Nurses (AMSN), Academy of Neonatal Nursing (ANN), American Academy of Ambulatory Care Nursing (AAACN), American Association of Critical-Care Nurses (AACN), American Association of Neuroscience Nurses (AANN), American Association of Nurse Practitioners (AANP), American Holistic Nurses Association (AHNA), American Nephrology Nurses Association (ANNA), American Nurses Association (ANA), American Psychiatric Nurses Association (APNA), American Society for Pain Management Nursing (ASPMN), Association for Radiologic and Imaging Nursing (ARIN), Association of Pediatric Hematology/Oncology Nurses (APHON), Association of Rehabilitation Nurses (ARN), Emergency Nurses Association (ENA), Gerontological Advanced Practice Nurses Association (GAPNA), Home Healthcare Nurses Association (HHNA), Hospice and Palliative Nurses Association (HPNA), Infusion Nurses Society (INS), International Transplant Nurses Society (ITNS), National Association of Clinical Nurse Specialists (NACNS), National Association of Directors of Nursing Administration (NADONA), National Association of Pediatric Nurse Practitioners (NAPNAP), Nurses Organization of Veterans Affairs (NOVA), Oncology Nursing Society (ONS), and the Wound Ostomy and Continence Nurses Society (WOCN). These organizations collectively represent over 610,000 members. The summit is also supported through the Institute for Healthcare Improvement and hosted by the George Washington University School of Nursing. The Palliative Nursing Summit was made possible through grants from the Milbank Foundation and the Hospice and Palliative Nurses Foundation. Those interested in the Palliative Nursing Summit can follow along through social media on Twitter and Facebook by using the #palliative, #nursingsummit, and #nursing hashtags. Additional information is online at advancingexpertcare.org/palliative-nursing-summit. About HPNA The Hospice and Palliative Nurses Association was established in 1986 and is the national professional organization that represents the specialty of palliative nursing, which includes hospice and palliative nurses. HPNA has over 11,500 members and 50 chapters nationally. HPNA works together with the Hospice and Palliative Credentialing Center and the Hospice and Palliative Nurses Foundation to promote our mission, to advance expert care in serious illness, and our vision, to transform the care and culture of serious illness. Visit hpna.advancingexpertcare.org to learn more. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/25-specialty-nursing-organizations-join-with-the-hospice-and-palliative-nurses-association-for-a-palliative-nursing-summit-may-12-in-washington-dc-300453369.html